GSK-25
GSK-25 is a potent, selective and orally bioavailable ROCK1 inhibitor (IC50=7 nM) . GSK-25 maintains good selectivity against a panel of 31 kinases (>100 fold), as well as RSK1 and p70S6K (RSK1: IC50=398 nM, p70S6K: IC50=1 μM) . GSK-25 inhibits P450 profile (IC50s of 2.5, 5.2, 2.5 μM for CYP2C9, CYP2D6, CYP3A4, respectively) [1].
Product Specifications
CAS Number
874119-56-9
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Ribosomal S6 Kinase (RSK) ; ROCK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Cytoskeleton; MAPK/ERK Pathway; Stem Cell/Wnt; TGF-beta/Smad
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/gsk-25.html
Concentration
10mM
Purity
99.68
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
ClC1=CC(C2=NC(C3=C(F)C=C(Cl)C=C3)C(C(NC4=C(F)C=C(NN=C5)C5=C4)=O)=C(C)N2)=CC=N1
Molecular Formula
C24H16Cl2F2N6O
Molecular Weight
513.33
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
SUMO-2 (SUMO2/1199), CF740 conjugate, 0.1mg/mL
(2R,3R,4S,5R)-1,2:4,5-Di-O-isopropylidene-3-nonadecanol
